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Abstract
Modern amyloid nomenclature, based on the amyloid fibril proteins, includes 
31 types of amyloidosis. Renal involvement is commonly seen in AA, AL, and 
several other hereditary and acquired amyloidoses. AA amyloidosis, constituting 
up to 45% of all systemic amyloidosis cases, is associated with wide variety of 
chronic inflammatory conditions. The precursor protein of the fibrils in AA amy-
loidosis is an apolipoprotein, called serum amyloid A, and produced in the liver 
in response to proinflammatory cytokines. AL amyloidosis is actually known to 
be the most common form of systemic amyloidosis in the Western countries. In 
this type of amyloidosis the precursor proteins are monoclonal immunoglobulin 
light chains, produced by plasma cell clone. Clinical diagnosis of AA and AL 
systemic amyloidosis is based on the presence of proteinuria or nephrotic syn-
drome and impaired kidney function in patients with extrarenal manifestations. 
Kidney biopsy is crucial for the diagnostics, and while Congo red staining with 
examination of Congo-positive material in the polarized light is confirmative for 
amyloidosis as such, immune staining, helpful to distinguish AA and AL types, 
guides treatment strategies. In cases when neither AA nor AL amyloidosis are 
confirmed, one should consider rare types of amyloidosis—ALECT2, AapolA, 
AFib or ALys.
Keywords: light chains, serum amyloid A, nephrotic syndrome, kidney function, 
kidney biopsy
1. Introduction
Modern amyloid nomenclature, based on the amyloid fibril proteins, includes 
31 types of amyloidosis [1]. Renal involvement is commonly seen in AL, AH, AA, 
ALECT2, and several other hereditary and acquired amyloidoses [1–4], main 
features are summarized in Table 1.
We describe below two most common types of amyloidosis, damaging  
kidneys—AA amyloidosis and AL amyloidosis.
2. AA amyloidosis
The precursor protein of the fibrils in AA amyloidosis is an apolipoprotein, 
called serum amyloid A, and produced in the liver in response to proinflammatory 
cytokines. AA amyloidosis, constituting up to 45% of all systemic amyloidosis 
cases, is associated with wide variety of chronic inflammatory conditions [5–7], 
summarized in the Table 2.
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Kidneys are the main site of involvement in AA amyloidosis, renal damage 
(Figure 1) occurs in 90% of cases, presenting with proteinuria, nephrotic syn-
drome (NS) and impaired kidney function [3, 6].
Rheumatoid arthritis, if poorly controlled, still remains one of the most com-
mon inflammatory diseases, associated with AA amyloidosis (Figure 2).
However, many other conditions, listed in Table 2, may be causative for AA 
amyloidosis. Frequency of the diseases, associated with AA amyloidosis in the 
patients, followed in our unit, is shown in Table 3.
Worthy to note, that beyond traditional causes, several rare conditions, such as 
sarcoidosis, cystic fibrosis and Castleman’s disease, complicated by AA amyloidosis, 
might be seen in the real practice (Figures 3 and 4).
Moreover, we recently described a patient with sclerosing angiomatoid nodu-
lar transformation of the spleen and AA amyloidosis [8], association previously 
unreported (Figures 5 and 6).
Presence of NS or proteinuria in patients with the history of any kind of chronic 
inflammatory conditions, indicates a high “suspicion index’ with AA amyloidosis. 
The diagnosis demands pathology confirmation with kidney biopsy, demonstrat-
ing not only positive Congo red staining of the material, infiltrating kidney tissue 
(see Figure 1), but also apple-green birefringence in polarized light (Figure 7) and 
serum amyloid A expression (Figure 8).
Treatment goal in patients with AA amyloidosis is a complete control of the 
inflammatory process [6]. Due to the various characters of the underlying diseases, 
treatment may include surgery, antibiotics, anti-TNF agents, colchicine and several 
novel drugs. Kidney transplantation for the patients with the end stage of renal 
disease (ESRD) is an important option and may be considered if a stable control of 
the underlying disease has been achieved.
Protein precursor Fibril 
protein
Clinical setting Kidney 
damage
Other target organs
Immunoglobulin 
light chain
AL “Primary” 
amyloidosis, LPD
70% All organs
Immunoglobulin 
heavy chain
AH LPD — All organs
Serum amyloid A AA Chronic 
inflammation
90% All organs except CNS
Leucocyte 
chemotactic factor-2
ALECT2 Not defined 
as acquired or 
hereditary
Primarily Liver
Transthyretin ATTR Hereditary and 
acquired
Common Heart, Eye, PNS, ANS, 
ligaments, tendon 
synovium, leptomeninges
Apolipoprotein A I AapoAI Hereditary Common Heart, liver, PNS, testis, 
larynx, skin
Apolipoprotein A II AapoAII Hereditary Primarily Many organs
Apolipoprotein A IV AapoAIV Acquired Primarily —
Fibrinogen α AFib Hereditary Primarily —
Lysozyme ALys Hereditary Primarily Liver
LPD, lymphoproliferative disorders; CNS, central nervous system; PNS, peripheral nervous system; ANS, autonomous 
nervous system.
Table 1. 
Amyloidoses with renal involvement.
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Infectious conditions with persistent 
inflammation
Chronic non-infectious diseases with persistent 
inflammation
Conditions predisposing to chronic infections
• Cystic fibrosis
• Epidermolysis bullosa
• Paraplegia
• Jejunoileal bypass
• Intravenous drugs use
Arthritis
• Rheumatoid arthritis
• Ankylosing spondylitis
• Adult Still disease
• Juvenile idiopathic arthritis
• Psoriatic arthritis
• Gout
Immunodeficiency’s predisposing to chronic infections
• Common variable immunodeficiency
• Hypogammaglobulinemia
• X-linked agammaglobulinemia
• Cyclic neutropenia
• HIV/AIDS
• Other immunodeficiencies
Bowel diseases
• Crohn’s disease
• Ulcerative colitis
Systemic vasculitis
• Behcet’s disease
• Polyarteritis nodosa
• Giant cell vasculitis
• Takayasu’s arteritis
• Polymyalgia rheumatica
Chronic infections
• Bronchiectasis
• Osteomyelitis
• Tuberculosis
• Leprosy
• Chronic pyelonephritis
• Whipple’s disease
• Chronic cutaneous ulcers
Other diseases
• Sarcoidosis
• SAPHO syndrome
• Schnitzler syndrome
• Rosai-Dorfman disease
• Recurrent idiopathic pericarditis
Neoplastic diseases
Blood malignancies
• Castleman’s disease
• Hodgkin’s lymphoma
• Waldenstrom macroglobulinemia
• Hairy cell leukemia
Solid tumors
• Hepatic adenoma
• Renal cell carcinoma
• Adenocarcinoma of the lung
• Adenocarcinoma of the gut
• Mesothelioma
Hereditary autoinflammatory syndromes
Classic
• Familial Mediterranean fever
Rare
• TRAPS
• Muckle-Wells syndrome
• NOMID/CINCA syndrome
• Hyper-IgD syndrome
• Other monogenic autoinflammatory syndromes
HIV, human immunodeficiency virus; AIDS, acquired immunodeficiency syndrome; SAPHO, synovitis, acne, 
pustules, hyperostosis, osteitis; TRAPS, TNF receptor associated periodic syndrome; NOMID, neonatal multisystem 
inflammatory disease; CINCA, chronic infantile neurological cutaneous and articular syndrome.
Table 2. 
Diseases, associated with AA amyloidosis.
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Figure 1. 
Renal AA amyloidosis, Congo red 100×.
Figure 2. 
Rheumatoid arthritis, complicated by renal AA amyloidosis with nephrotic syndrome.
Associated disease Patients (N) %
Rheumatoid arthritis 64 44.1
Ankylosing spondylitis 16 11.0
Psoriatic arthritis 7 4.8
Crohn’s disease/ulcerative colitis 3 2.0
Sarcoidosis 1 0.7
Mediterranean fever 14 9.6
Hyper-IgD syndrome 1 0.7
Bronchiectasis 10 6.8
Osteomyelitis 7 4.8
Paraplegia 6 4.1
Tuberculosis 4 2.7
Chronic cutaneous ulcers 3 2.0
Cystic fibrosis 1 0.7
Lung tumors 3 2.0
Hodgkin’s lymphoma 2 1.4
Castleman’s disease 2 1.4
Sclerosing angiomatoid nodular transformation of the spleen 1 0.7
Total 145 100
Table 3. 
Spectrum of the diseases, associated with AA amyloidosis, personal data, unpublished.
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Figure 3. 
Castleman’s disease, unfixed gross specimen.
Figure 4. 
Castleman’s disease, atypical lymphoid tissue, hematoxylin & eosin 100×.
Figure 5. 
Sclerosing angiomatoid nodular transformation of the spleen. Formalin-fixed gross specimen.
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3. AL amyloidosis
The precursor proteins of the fibrils in AL amyloidosis are monoclonal immuno-
globulin light chains, produced by plasma cell clone. AL amyloidosis, which is the 
most prevalent type of systemic amyloidosis in the Western countries, sometimes 
Figure 6. 
Sclerosing angiomatoid nodular transformation of the spleen. PAS 100×.
Figure 7. 
Renal AA amyloidosis, Congo red 100×, polarized light.
Figure 8. 
Renal AA amyloidosis, serum amyloid A, immunoperoxidase 100×.
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is associated with B cell lymphoproliferative disorders—multiple myeloma, 
Waldenström macroglobulinemia and non-Hodgkin lymphomas [9–14]. However 
usually AL amyloidosis is associated with low-grade plasma cell clone and do not 
meet the criteria for multiple myeloma or lymphoplasmacytic lymphoma, therefore 
formerly it was known as “primary” [15–18].
In the real practice, among 128 patients with biopsy-proven AL amyloidosis, fol-
lowed in our unit, 25 were diagnosed with multiple myeloma, 1—with Waldenström 
macroglobulinemia, and 102—with AL amyloidosis (“primary”).
Kidneys and heart are the main sites of involvement in AL amyloidosis with the 
occurrence up to 70% of cases. Renal involvement typically presents with protein-
uria or NS, which is manifested in more than 50% of patients at the time of diagno-
sis, and impaired kidney function progressing towards ESRD in about 20% of cases 
over time [19–21].
AL amyloidosis is diagnosed by demonstration of monoclonal deposits in the 
sites of amyloid deposition in the kidney (Figures 9–11).
Kidney biopsy is usually indicated for significant proteinuria and/or renal 
insufficiency in patients with signs and symptoms of heart, liver, tongue, 
intestine, peripheral and autonomous nervous system and soft tissues damage 
(Figures 12–17).
Monoclonal protein studies should be performed to match the monoclonal 
protein in circulation with the monoclonal deposits in the kidney (Figure 18).
Figure 9. 
Renal AL amyloidosis, Congo red 100×.
Figure 10. 
Renal AL amyloidosis, Congo red 100×, polarized light.
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Different treatment regimens had been used since 1997, when melphalan was 
introduced—melphalan and prednisone (MP), melphalan and dexamethasone 
(MD), and high dose melphalan with autologous stem cell transplantation (ASCT). 
Figure 11. 
Renal AL amyloidosis, light chain lambda, immunofluorescence 100×.
Figure 12. 
AL amyloidosis, electrocardiogram, low-voltage waves in all leads.
Figure 13. 
AL amyloidosis, echocardiogram, myocardial mirror-like appearance.
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Figure 16. 
AL amyloidosis, “racoon eye” symptom.
Figure 14. 
AL amyloidosis, macroglossia.
Figure 15. 
AL amyloidosis, “shoulder pad” symptom.
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Figure 17. 
AL amyloidosis, spontaneous subcutaneous hemorrhages.
Figure 18. 
Serum electrophoresis, M-spike.
Figure 19. 
Treatment results in 49 patients with AL amyloidosis, personal data [23].
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Currently recommended treatment for AL amyloidosis, including cyclophospha-
mide-thalidomide-dexamethasone (CTD), bortezomib-dexamethasone (BD), 
cyclophosphamide-bortezomib-dexamethasone(CBD) regimens with relatively fast 
hematological response were adopted from multiple myeloma treatment protocols 
[22]. In our experience of treatment of systemic “primary” AL amyloidosis with 
kidney involvement using different regimens over almost three decades, cumulative 
survival did not differ statistically between melphalan-based and bortezomib-based 
regimens (Figure 19) [23].
4. Conclusions
Clinical diagnosis of AA and AL systemic amyloidosis, most often affecting kid-
neys, is based on the presence of proteinuria or nephrotic syndrome and impaired 
kidney function in patients with extrarenal manifestations. Kidney biopsy is crucial 
for the diagnostics, and while Congo red staining with examination of Congo-
positive material in the polarized light is confirmative for amyloidosis as such, 
immunofluorescence and immunohistochemistry technics are helpful to distinguish 
AA and AL types. Differential diagnostics of AA and AL types guides the treatment 
strategies. In cases when neither AA nor AL amyloidosis are confirmed, one should 
consider rare types of amyloidosis, based on the presence of renal involvement—
ALECT2, AapolA I, II and IV, AFib or ALys amyloidosis.
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